Table 1 Relative survival by diagnostic group and age at diagnosis when diagnosed in 2000–2013 in Denmark, Finland, Norway or Sweden

From: Survival after cancer in children, adolescents and young adults in the Nordic countries from 1980 to 2013

ICCC-3 diagnostic group

Age at diagnosis

N

Deaths

Relative 5-year survival in % (95% CI)

p-value

Cancers/deaths

1.a Lymphoid leukaemias (ALL)

0–14

2088

191

90 (88–91)

<0.0001

 
 

15–24

406

94

73 (69–78)

–

2705/341

 

25–34

211

56

70 (63–77)

0.39

 

1.b Acute myeloid leukaemias (AML)

0–14

388

93

74 (70–79)

0.18

 
 

15–24

252

70

69 (63–76)

–

959/274

 

25–34

319

111

62 (56–68)

0.09

 

2.a Hodgkin lymphomas (HL)

15–24

1473

37

97 (96–98)

–

2709/86

 

25–34

1236

49

96 (94–97)

0.06

 

2.b non-Hodgkin lymphomas (NHL)

0–14

312

29

90 (87–94)

0.07

 
 

15–24

498

66

86 (83–89)

–

1770/203

 

25–34

960

108

87 (85–90)

0.39

 

3.b Astrocytomas

0–14

823

122

84 (81–86)

0.0017

 
 

15–24

512

105

76 (72–80)

–

2015/493

 

25–34

680

266

55 (51–59)

<0.0001

 

3.c Intracranial and intraspinal embryonal tumours

0–14

408

134

64 (59–69)

0.98

 
 

15–24

77

25

64 (53–77)

–

519/175

 

25–34

34

16

38 (22–67)

0.08

 

3.d Other gliomas

0–14

121

37

67 (59–76)

0.09

 
 

15–24

153

30

77 (70–85)

–

618/130

 

25–34

344

63

78 (73–83)

0.86

 

3.e Other specified intracranial and intraspinal neoplasms

0–14

325

14

95 (92–98)

0.21

 
 

15–24

427

11

97 (95–99)

–

1489/43

 

25–34

737

18

98 (96–99)

0.68

 

7.x Hepatic tumour—othera

0–14

30

12

45 (27–74)

0.39

 
 

15–24

26

13

30 (13–67)

–

136/69

 

25–34

80

44

31 (19–50)

0.92

 

8.a Osteosarcomas

0–14

172

40

73 (66–80)

0.11

 
 

15–24

176

57

64 (57–72)

–

397/111

 

25–34

49

14

69 (56–84)

0.58

 

8.c Ewing tumour and related sarcomas of bone

0–14

136

39

69 (61–77)

0.19

 
 

15–24

108

38

59 (50–71)

–

244/77

9.a Rhabdomyosarcomas

0–14

236

56

72 (66–78)

0.015

 
 

15–24

64

27

50 (38–66)

–

300/83

9.x NRSTSb

0–14

203

22

88 (83–93)

<0.0001

 
 

15–24

397

91

74 (69–79)

–

1207/231

 

25–34

607

118

79 (75–82)

0.09

 

a.c Malignant gonadal germ cell tumours

15–24

1896

37

98 (97–99)

–

6115/111

 

25–34

4219

74

98 (98–99)

0.49

 

b.d Malignant melanomas

15–24

1291

48

96 (94–97)

–

5564/251

 

25–34

4273

203

95 (94–95)

0.20

 

b.f.6 Carcinomas of breast

15–24

121

13

87 (81–94)

 

2708/382

 

25–34

2587

369

82 (80–84)

0.12

 

b.f.7 Carcinomas of cervix uteric

15–24

182

19

89 (84–94)

 

1980/144

 

25–34

1798

125

93 (92–94)

0.12

 

All analysed cancers

0–14

5242

789

   
 

15–24

8059

781

  

31,435/3204

 

25–34

18134

1634

   
  1. a“7.x Hepatic tumour—Other” is 7. “Hepatic tumours” excluding “7.a Hepatoblastoma” in the international Classification of Childhood Cancer, Third Edition (ICCC-3)17
  2. b“9.x NRSTS” is “9. Soft tissue and other extraosseous sarcomas” excluding “9.a Rhabdomyosarcomas” in ICCC-3
  3. cNumbers regarding “b.f.7 Carcinoma of cervix uteri” are based only on Denmark, Finland and Norway
Back to article page